Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Peroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer

Authors: Michele Linsalata, Romina Giannini, Maria Notarnicola, Aldo Cavallini

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

The peroxisome proliferator-activated receptor γ (PPARγ) is a transcription factor that regulates adipogenic differentiation and glucose homeostasis. Spermidine/spermine N1-acetyltransferase (SSAT) and ornithine decarboxylase (ODC) are key enzymes involved in the metabolism of polyamines, compounds that play an important role in cell proliferation. While the PPARγ role in tumour growth has not been clearly defined, the involvement of the altered polyamine metabolism in colorectal carcinogenesis has been established. In this direction, we have evaluated the PPARγ expression and its relationship with polyamine metabolism in tissue samples from 40 patients operated because of colorectal carcinoma. Since it is known that the functional role of K-ras mutation in colorectal tumorigenesis is associated with cell growth and differentiation, polyamine metabolism and the PPARγ expression were also investigated in terms of K-ras mutation.

Methods

PPARγ, ODC and SSAT mRNA levels were evaluated by reverse transcriptase and real-time PCR. Polyamines were quantified by high performance liquid chromatography (HPLC). ODC and SSAT activity were measured by a radiometric technique.

Results

PPARγ expression, as well as SSAT and ODC mRNA levels were significantly higher in cancer as compared to normal mucosa. Tumour samples also showed significantly higher polyamine levels and ODC and SSAT activities in comparison to normal samples. A significant and positive correlation between PPARγ and the SSAT gene expression was observed in both normal and neoplastic tissue (r = 0.73, p < 0.0001; r = 0.65, p < 0.0001, respectively). Moreover, gene expression, polyamine levels and enzymatic activities were increased in colorectal carcinoma samples expressing K-ras mutation as compared to non mutated K-ras samples.

Conclusion

In conclusion, our data demonstrated a close relationship between PPARγ and SSAT in human colorectal cancer and this could represent an attempt to decrease polyamine levels and to reduce cell growth and tumour development. Therefore, pharmacological activation of PPARγ and/or induction of SSAT may represent a therapeutic or preventive strategy for treating colorectal cancer.
Appendix
Available only for authorised users
Literature
1.
Rosen ED, Spiegelman BM: PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001, 276: 37731-37734.CrossRefPubMed
2.
Lefebvre A-M, Paulweber B, Fajas L, Woods J, McCrary C, Colombel J-F, Najib J, Fruchart J-C, Datz C, Vidal H, Desreumaux P, Auwerx J: Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol. 1999, 162: 331-334.CrossRefPubMed
3.
Koeffler HP: Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res. 2003, 9: 1-9.PubMed
4.
Auwerx J: Nuclear receptors. PPARγ in the gastrointestinal tract: gain or pain?. Am J Physiol Gastrointest Liver Physiol. 2002, 282: G581-G585.CrossRefPubMed
5.
Babbar N, Ignatenko NA, Casero RA, Gerner EW: Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem. 2003, 278: 47762-47775.CrossRefPubMed
6.
7.
Linsalata M, Caruso MG, Leo S, Guerra V, D'Attoma B, Di Leo A: Prognostic value of tissue polyamine levels in human colorectal carcinoma. Anticancer Res. 2002, 22: 2465-2470.PubMed
8.
Notarnicola M, Linsalata M, Caruso M, Caruso ML, Altomare D, Lorusso D, Leo S, Di Leo A: Genetic and biochemical changes in colorectal carcinoma in relation to morphologic characteristics. Oncol Rep. 2003, 10: 1987-1991.PubMed
9.
10.
Seiler N: Catabolism of polyamines. Amino Acids. 2004, 26: 217-233.PubMed
11.
Kee K, Foster BA, Merali S, Kramer DL, Hensen ML, Diegelman P, Kisiel N, Vujcic S, Mazurchuk RV, Porter CW: Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice. J Biol Chem. 2004, 38: 40076-40083.CrossRef
12.
Wallace HM, Duthie J, Evans DM, Lamond S, Nicoll KM, Heyes SD: Alterations in polyamine catabolic enzymes in human breast cancer tissue. Clin Cancer Res. 2000, 6: 3657-3661.PubMed
13.
Takashima T, Fujiwara Y, Higuchi K, Arakawa T, Yano Y, Hasuma T: PPAR-γ ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol. 2001, 19: 465-471.PubMed
14.
Linsalata M, Notarnicola M, Caruso MG, Di Leo A, Guerra V, Russo F: Polyamine biosynthesis in relation to K-ras and p-53 mutations in colorectal carcinoma. Scand J Gastroenterol. 2004, 39: 470-477.CrossRefPubMed
15.
Ignatenko NA, Babbar N, Mehta D, Casero RA, Gerner EW: Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol Carcinog. 2004, 39: 91-102.CrossRefPubMed
16.
Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Verlind E, Hermans J, Poppema S, Buys CH, Plukker JT: Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis Colon Rectum. 2001, 44: 358-363.CrossRefPubMed
17.
Giannini R, Cavallini A: Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma. Anticancer Res. 2005, 25: 4287-4292.PubMed
18.
Wallace HM, Evans DM: Measurement of spermidine/spermine N1-acetyltransferase activity. Methods in molecular biology. Edited by: David ML Morgan. 1998, Totowa: Humana Press Inc, 79: 59-68.
19.
Karger S, Berger K, Eszlinger M, Tannapfel A, Dralle H, Paschke R, Fuhrer D: Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies. Thyroid. 2005, 15: 997-1003.CrossRefPubMed
20.
Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE: Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer. 2005, 92: 113-119.CrossRefPubMed
21.
Therashita Y, Sasaki H, Haruki N, Nishiwaki T, Ishiguro H, Shibata Y, Kudo J, Konishi S, Kato J, Koyama H, Kimura M, Sato A, Shinoda N, Kuwabara Y, Fujii Y: Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol. 2002, 32: 238-243.CrossRef
22.
Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med. 1998, 4: 1046-1052.CrossRefPubMed
23.
Feilchenfeldt J, Brundler MA, Soravia C, Totsch M, Meier CA: Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARγ-coactivator 1 (PGC-1). Cancer Lett. 2004, 203: 25-33.CrossRefPubMed
24.
DuBois R, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA: The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis. 1998, 19: 49-53.CrossRefPubMed
25.
Lefebvre AM, Chen I, Desreumaux P, Naijb J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J: Activation of the peroxisome proliferator activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+mice. Nat Med. 1998, 4: 1053-1057.CrossRefPubMed
26.
Shimava T, Kojima K, Yoshiura K, Hiraishi H, Terano A: Characteristics of peroxisome proliferators-activated receptor gamma (PPARγ) ligand induced apoptosis in colon cancer cells. Gut. 2002, 50: 658-664.CrossRef
27.
Kohno H, Suzuki R, Sugie S, Tanaka T: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer. 2005, 5: 46-CrossRefPubMedPubMedCentral
28.
Linsalata M, Russo F, Notarnicola M, Guerra V, Cavallini A, Clemente C, Messa C: Effects of genistein on the polyamine metabolism and cell growth in DLD-1 human colon cancer cells. Nutr and Cancer. 2005, 52: 83-92.CrossRef
29.
Thomas T, Thomas TJ: Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci. 2001, 58: 244-258.CrossRefPubMed
30.
Chen Y, Kramer DL, Jell j, Vujcic S, Porter CW: Small interfering RNA suppression of polyamine analog-induced spermidine/spermine N1-acetyltransferase. Mol Pharmacol. 2003, 64: 1153-1159.CrossRefPubMed
31.
Kee K, Vujcic S, Merali S, Diegelman P, Kisiel N, Powell CT, Kramer DL, Porter CW: Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells. J Biol Chem. 2004, 279: 27050-27058.CrossRefPubMed
32.
Tucker JM, Murphy JT, Kisiel N, Diegelman P, Barbour KW, Davis C, Medda M, Alhonen L, Janne J, Kramer DL, Porter CW, Berger FG: Potent modulation of intestinal tumorigenesis in Apcmin/+ mice by the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase. Cancer Res. 2005, 65: 5390-5398.CrossRefPubMed
33.
Vujcic S, Halmekyto M, Diegelman p, Gan G, Kramer DL, Janne J, Porter CW: Effects of conditional of overexpression of spermidine-spermine N1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem. 2000, 275: 38319-38328.CrossRefPubMed
34.
Kee K, Vujcic S, Merali S, Diegelman P, Kisiel N, Powell CT, Kramer DL, Porter CW: Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells. J Biol Chem. 2004, 279: 27050-27058.CrossRefPubMed
35.
Linsalata M, Russo F, Cavallini A, Berloco P, Di Leo A: Polyamines, diamine oxidase, and ornithine decarboxylase activity in colorectal cancer and in normal surrounding mucosa. Dis Colon Rectum. 1993, 36: 662-667.CrossRefPubMed
36.
Linsalata M, Cavallini A, Di Leo A: Polyamine oxidase activity and polyamine levels in human colorectal cancer and in normal surrounding mucosa. Anticancer Res. 1997, 17: 3757-3760.PubMed
37.
Weiss T, Bernhardt G, Buschauer A, Thasler WA, Dolgner D, Zirngibl H, Jauch KW: Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade. Int J Colorectal Dis. 2002, 17: 381-387.CrossRefPubMed
38.
Naso P, Lantieri R, Acquaviva R, Licata F, Bonanno G, Licata A: Polyamines levels in colorectal cancer: new markers?. Hepatogastroenterol. 2005, 52: 433-436.
39.
Russo F, Linsalata M, Giorgio I, Caruso ML, Armentano R, Di Leo A: Polyamine levels and ODC activity in intestinal-type and diffuse-type gastric carcinoma. Dig Dis Sci. 1997, 42: 576-579.CrossRefPubMed
40.
Basuroy UK, Gerner EW: Emerging concepts in targeting thepolyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J Biochem. 2006, 139: 27-33.CrossRefPubMed
Metadata
Title
Peroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer
Authors
Michele Linsalata
Romina Giannini
Maria Notarnicola
Aldo Cavallini
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-191

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Homeostatic response under carcinogen withdrawal, heme oxygenase 1 expression and cell cycle association

Research article

Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data

Research article

A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

Research article

Ethnic differences in the time trend of female breast cancer incidence: Singapore, 1968 – 2002

Research article

KIAA0101 (OEACT-1), an expressionally down-regulated and growth-inhibitory gene in human hepatocellular carcinoma

Research article

Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits